Research
Hormonal
Ramipril is associated with lower rates of new diagnosis of diabetes in high-risk individuals, with 3.6% in the ramipril group developing diabetes compared to 5.4% in the placebo group (RR, 0.66; P<.001).
Practitioners may consider ramipril as a preventive strategy for diabetes in high-risk patients.
StrongSupportsmedium confidence
One hundred and two individuals (3.6%) in the ramipril group developed diabetes compared with 155 (5.4%) in the placebo group (relative risk [RR], 0.66; 95% confidence interval [CI], 0.51-0.85, P<.001).
Why this rating
Based on a large randomized controlled trial design.
Source
Ramipril and the Development of Diabetes
Salim Yusuf · JAMA · 2001
rct · n=5720Cited 546×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →